Microtech Launches Groundbreaking Atrial Microsensor Implant Study in the U.S.

Microtech, a subsidiary wholly owned by Medinol, is leading the charge in cardiac healthcare innovation by announcing its first atrial microsensor implantations in the United States. The groundbreaking study commenced with two successful implants conducted on May 16, 2025, at the prestigious New York-Presbyterian/Columbia University Irving Medical Center. The procedures were expertly carried out by Dr. Koji Takeda, the center's director of heart transplant surgery.

The atrial microsensor represents an advanced class of medical devices, characterized by its remarkably compact size, absence of electronics and antennas, and capacity for signal transmission via ultrasound. These features allow the Microtech sensors to operate as standalone devices, or be integrated with existing medical implants, transforming them into sophisticated, data-collecting therapeutic and diagnostic smart devices.

The initial implants added to the five microsensors that had previously been placed in patients in Israel under similar clinical conditions. Dr. Takeda commented on the simplicity and efficiency of the procedure, stating that the microsensor implantation took only about five minutes, requiring minimal modification to the existing left ventricular assist device (LVAD) implantation protocol.

“Having the capability for non-invasive monitoring of pressures measured in both left and right cardiac structures is poised to greatly enhance our capacity for optimizing patient care. This transition from observing symptoms to employing parameter-driven therapies is a game changer,” expressed Dr. Nir Uriel, director of advanced heart failure and heart transplantation at New York-Presbyterian, who also serves as the study’s principal investigator. He emphasized that the ability to measure these pressures has so far proven to be easy, repeatable, and accurate across all participating patients.

Dr. Uriel, who is also an associate professor in the Greenberg Division of Cardiology at Weill Cornell Medicine and a professor of cardiology at the Vagelos College of Physicians and Surgeons at Columbia University, noted the collaboration’s significance in furthering cardiac health advancements.

The Microtech FIH study is designed to enroll a total of 15 patients across both Israel and the United States. Medinol's CEO, Dr. Yoram Richter, expressed enthusiasm about the study's progress, noting, “We are thrilled with the sensor’s performance and are excited to demonstrate the system’s feasibility, utility, and precision moving forward. Simultaneously, we are exploring the integration of these microsensors into existing medical devices, striving for the promises this technology holds.”

Medinol is revolutionizing disease diagnosis and treatment by developing cutting-edge medical devices for stent implantation in various parts of the body, significantly reducing complications from structural heart procedures. By providing real-time physiological parameter information through implantable sensors, Medinol is boldly modernizing existing technologies and procedures, looking far into the future to create new medical products and enhance physicians' capabilities spatially and physically. Through partnerships with medical professionals and industry stakeholders, Medinol is shaping the future of healthcare today.

For additional information, visit www.medinol.com. For inquiries, contact Jeff Roach, Sales Director, at [email protected]